Latest Articles

How swine viruses spread
Others

How swine viruses spread: Delving into airborne transmission

  • 30 minutes

“We know that vaccinating can decrease the amount of viruses in the air, so vaccination is a good mechanism to prevent airborne transmission” Swine veterinary consultant Dr. Carmen Alonso in Spain picks out lessons from her detailed studies of air samples inside and outside farms suffering an outbreak of PRRS, influenza A or porcine epidemic diarrhoea --- as well as poultry sites with highly pathogenic avian influenza.

Professor Segalés shares
Others

PCV3: Emerging pathogen or incidental finding?

  • 30 minutes

“Our recent work demonstrated the presence of the PCV-3 genome within mild-to moderate histological lesions of aborted fetuses.

Dr. Mike Murtaugh discusses
Others

Do PCV2-a based vaccines cross protect?

  • 2 minutes

In this video Dr. Mike Murtaugh discusses vaccine cross-protection on various PCV2 strains: PCV2a, PCV2b & PCV2d. He also talks about the outbreaks of PCVAD and how correct usage of the vaccine is key.

It can be of your interest
STRONG ACTIVE PIGLETS VERSUS INTRA-UTERINE GROWTH-RATE RESTRICTED (IUGR)-PIGLETS
Others

STRONG ACTIVE PIGLETS VERSUS INTRA-UTERINE GROWTH-RATE RESTRICTED (IUGR)-PIGLETS

  • 5 minutes

A typical situation: farrowing was planned for the Thursday but many sows have already farrowed by Tuesday. Weak piglets lead to low milk-release of the sow.

BECAL Pig Image
Tool

BECAL Pig

BECAL (The Boehringer Ingelheim Economic Calculator) was created in collaboration with industry experts to provide a convenient tool for the economic analysis of vaccination interventions. The tool evaluates preventative health measures by easily calculating return on investment and benefit-cost ratios based on your production data. BECAL enables effective and proactive planning to help you to shape the future of swine health.

 Circovirus

BOEHRINGER INGELHEIM SEES ADVANTAGES OF FRESHLY MIXED VACCINE

  • 5 minutes

Boehringer Ingelheim Animal Health has decided to remain focused on freshly mixed Porcine Circovirus type 2 (PCV2)/ Mycoplasma hyopneumoniae (M.hyo) vaccines and not follow the development of a PCV2/M.hyo ready-to-use (RTU) vaccine combination. As a consequence of this decision, the company has discontinued its PCV2/M.hyo RTU research program.